Scale-Up Right First Time With Allegro™ STR Bioreactors

Read what Divya Goel, VP of Business Development at Celltheon, has to say about the Allegro STR bioreactor

"The Allegro platform is an integrated, highly scalable manufacturing solution making process development and subsequent production more streamlined. By addressing previous limitations of key scalability parameters such as P/V, the time and resources spent on scale-up is reduced. Thus, the impact of this platform is reduction in timeline and COGS which directly benefits patients.”
 
"Many biosimilar developers are successful in developing a ‘bench-scale’ biosimilar but when they scale up, they lose productivity and/or quality preventing these programs from being commercially viable. The first generation of single-use bioreactors had certain limitations; the Allegro platform has addressed many of these concerns making it unique in replicating bench scale processes. It is truly a scalable platform."

Divya Goel, MBS
Vice President of Business Development
Celltheon Corporation

I was pleasantly surprised at the speed and quality of the process development work performed by Pall Biotech’s SLS and PDS teams. Both groups were proactive, transparent, and maintained a high level of communication. The outcome of using Pall’s Cadence BioSMB platform was the significant reduction of sorbent use per gram of material. These results were first simulated and subsequently confirmed using the bench scale continuous multi-column chromatography BioSMB platform.